|
1
|
Llovet JM and Bruix J: Molecular targeted
therapies in hepatocellular carcinoma. Hepatology. 48:1312–1327.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rabinovich GA, Gabrilovich D and Sotomayor
EM: Immunosuppressive strategies that are mediated by tumor cells.
Annu Rev Immunol. 25:267–296. 2007. View Article : Google Scholar
|
|
3
|
Ostrand-Rosenberg S: Immune surveillance:
a balance between protumor and antitumor immunity. Curr Opin Genet
Dev. 18:11–18. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Borghaei H, Smith MR and Campbell KS:
Immunotherapy of cancer. Eur J Pharmacol. 625:41–54. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zarour HM and Ferrone S: Cancer
immunotherapy: Progress and challenges in the clinical setting. Eur
J Immunol. 41:1510–1515. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Van der Burg SH, Bijker MS, Welters MJ, et
al: Improved peptide vaccine strategies, creating synthetic
artificial infections to maximize immune efficacy. Adv Drug Deliv
Rev. 58:916–930. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bijker MS, Melief CJ, Offringa R and van
der Burg SH: Design and development of synthetic peptide vaccines:
past, present and future. Expert Rev Vaccines. 6:591–603. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Brunsvig PF, Kyte JA, Kersten C, et al:
Telomerase peptide vaccination in NSCLC: a phase II trial in stage
III patients vaccinated after chemoradiotherapy and an 8-year
update on a phase I/II trial. Clin Cancer Res. 17:6847–6857. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Joshi VG, Dighe VD, Thakuria D, et al:
Multiple antigenic peptide (MAP): a synthetic peptide dendrimer for
diagnostic, antiviral and vaccine strategies for emerging and
re-emerging viral diseases. Indian J Virol. 24:312–320. 2013.
View Article : Google Scholar :
|
|
10
|
Vlodavsky I, Ilan N, Naggi A and Casu B:
Heparanase: structure, biological functions, and inhibition by
heparin-derived mimetics of heparin sulfate. Curr Pharm Des.
13:2057–2073. 2007. View Article : Google Scholar
|
|
11
|
Vlodavsky I, Elkin M, Abboud-Jarrous G, et
al: Heparanase: one molecule with multiple functions in cancer
progression. Connect Tissue Res. 49:207–210. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Roy M and Marchetti D: Cell surface
heparan sulfate released by heparanase promotes melanoma cell
migration and angiogenesis. J Cell Biochem. 106:200–209. 2009.
View Article : Google Scholar :
|
|
13
|
Nasser NJ, Avivi A, Shafat I, et al:
Alternatively spliced Spalax heparanase inhibits extracellular
matrix degradation, tumor growth, and metastasis. Proc Natl Acad
Sci USA. 106:2253–2258. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Vlodavsky I, Goldshmidt O, Zcharia E, et
al: Mammalian heparanase: involvement in cancer metastasis,
angiogenesis and normal development. Semin Cancer Biol. 12:121–129.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
McKenzie EA: Heparanase: a target for drug
discovery in cancer and inflammation. Br J Pharmacol. 151:1–14.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sommerfeldt N, Beckhove P, Ge Y, et al:
Heparanase: a new metastasis-associated antigen recognized in
breast cancer patients by spontaneously induced memory T
lymphocytes. Cancer Res. 66:7716–7723. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Miao HQ, Liu H, Navarro E, et al:
Development of heparanase inhibitors for anti-cancer therapy. Curr
Med Chem. 13:2101–2111. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tang XD, Wan Y, Chen L, et al:
H-2Kb-restricted CTL epitopes from mouse heparanase elicit an
antitumor immune response in vivo. Cancer Res. 68:1529–1537. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liang XJ, Yuan L, Hu J, et al:
Phosphomannopentaose sulfate (PI-88) suppresses angiogenesis by
downregulating heparanase and vascular endothelial growth factor in
an oxygen-induced retinal neovascularization animal model. Mol Vis.
18:1649–1657. 2012.PubMed/NCBI
|
|
20
|
Dredge K, Hammond E, Handley P, et al:
PG545, a dual heparanase and angiogenesis inhibitor, induces potent
anti-tumour and anti-metastatic efficacy in preclinical models. Br
J Cancer. 104:635–642. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
He X, Brenchley PE, Jayson GC, et al:
Hypoxia increases heparanase-dependent tumor cell invasion, which
can be inhibited by antiheparanase antibodies. Cancer Res.
64:3928–3933. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Borsig L, Vlodavsky I, Ishai-Michaeli R,
et al: Sulfated hexasaccharides attenuate metastasis by inhibition
of P-selectin and heparanase. Neoplasia. 13:445–452.
2011.PubMed/NCBI
|
|
23
|
Du L, Wang HJ, Yang JM, et al: T-helper
epitope peptide improves immunological effects of the B cell
epitopes of human heparanase protein. Chin J Microbiol Immunol.
28:869–872. 2008.
|
|
24
|
Yang JM, Wang HJ, Du L, et al: Screening
and identification of novel B cell epitopes in human heparanase and
their anti-invasion property for hepatocellular carcinoma. Cancer
Immunol Immunother. 58:1387–1396. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu X, Cai M, Wang X and Li X: One simple
and efficient method for purification of IgG McAb from mice
ascites: caprylic acid/ammonium sulfate precipitation. Hua Xi Yi Ke
Da Xue Xue Bao. 30:455–456. 1999.(In Chinese).
|
|
26
|
Weidner N: Intratumor microvessel density
as a prognostic factor in cancer. Am J Pathol. 147:9–19.
1995.PubMed/NCBI
|
|
27
|
Bridges JF, Dong L, Gallego G, et al:
Prioritizing strategies for comprehensive liver cancer control in
Asia: a conjoint analysis. BMC Health Serv Res. 12:3762012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Aravalli RN, Cressman EN, Steer CJ, et al:
Cellular and molecular mechanisms of hepatocellular carcinoma: an
update. Arch Toxicol. 87:227–247. 2013. View Article : Google Scholar
|
|
29
|
Darzynkiewicz Z: Will cancer immunotherapy
fail? Scientist. 20:142006.
|
|
30
|
Kratky W, Reis e Sousa C, Oxenius A and
Spörri R: Direct activation of antigen-presenting cells is required
for CD8+ T-cell priming and tumor vaccination. Proc Natl
Acad Sci USA. 108:17414–17419. 2011. View Article : Google Scholar
|
|
31
|
Koop A, Sellami N, Adam-Klages S, et al:
Down-regulation of the cancer/testis antigen 45 (CT45) is
associated with altered tumor cell morphology, adhesion and
migration. Cell Commun Signal. 11:412013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Weldon JE, Xiang L, Zhang J, et al: A
recombinant immunotoxin against the tumor-associated antigen
mesothelin reengineered for high activity, low off-target toxicity,
and reduced antigenicity. Mol Cancer Ther. 12:48–57. 2013.
View Article : Google Scholar :
|
|
33
|
Vonderheide RH: Universal tumor antigens
for cancer vaccination: targeting telomerase for immunoprevention.
Discov Med. 7:103–108. 2007.PubMed/NCBI
|
|
34
|
Zhang YF, Tang XD, Gao JH, et al:
Heparanase: a universal immunotherapeutic target in human cancers.
Drug Discov Today. 16:412–417. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Palena C and Schlom J: Vaccines against
human carcinomas: strategies to improve antitumor immune responses.
J Biomed Biotechnol. 2010:3806972010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zou W: Regulatory T cells, tumour immunity
and immunotherapy. Nat Rev Immunol. 6:295–307. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bonertz A, Weitz J, Pietsch DH, et al:
Antigen-specific Tregs control T cell responses against a limited
repertoire of tumor antigens in patients with colorectal carcinoma.
J Clin Invest. 119:3311–3321. 2009.PubMed/NCBI
|
|
38
|
Ilan N, Elkin M, Vlodavsky I, et al:
Regulation, function and clinical significance of heparanase in
cancer metastasis and angiogenesis. Int J Biochem Cell Biol.
38:2018–2039. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Katz M, Lynn M, Solotorovsky M, et al:
Serological and biological activities of anti-Haemophilus
influenzae ribosomal serum. Infect Immun. 31:1125–1131.
1981.PubMed/NCBI
|
|
40
|
Levy-Adam F, Abboud-Jarrous G, Guerrini M,
et al: Identification and characterization of heparin/heparan
sulfate binding domains of the endoglycosidase heparanase. J Biol
Chem. 280:20457–20466. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Fidler IJ and Ellis LM: The implications
of angiogenesis for the biology and therapy of cancer metastasis.
Cell. 79:185–188. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
An FQ, Matsuda M, Fujii H and Matsumoto Y:
Expression of vascular endothelial growth factor in surgical
specimens of hepatocellular carcinoma. J Cancer Res Clin Oncol.
126:153–160. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Poon RT, Ng IO, Lau C, et al: Serum
vascular endothelial growth factor predicts venous invasion in
hepatocellular carcinoma: a prospective study. Ann Surg.
233:227–235. 2011. View Article : Google Scholar
|
|
44
|
Yang P, Yuan W, He J, et al:
Overexpression of EphA2, MMP-9, and MVD-CD34 in hepatocellular
carcinoma: implications for tumor progression and prognosis.
Hepatol Res. 39:1169–1177. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Xu YZ, Zhu Y, Shen ZJ, et al: Significance
of heparanase-1 and vascular endothelial growth factor in
adrenocortical carcinoma angiogenesis: potential for therapy.
Endocrine. 40:445–451. 2011. View Article : Google Scholar : PubMed/NCBI
|
